Click on headlines below to download research
No surprises in FY18 annual report
ASIT biotech | 17/05/2019
ASIT biotech published its preliminary FY18 results in early April, including the cash position at the end of March 2019, and issued its FY18 report in…
All the bases loaded for ASIT011
ASIT biotech | 03/04/2019
ASIT’s FY18 preliminary results were dominated by the initiation of the second Phase III study of gp-ASIT+ where randomisation is now complete. The…
Supportive data on ASIT’s short-course therapy
ASIT biotech | 14/03/2019
ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…
Supportive data on ASIT’s short-course therapy
ASIT biotech | 06/03/2019
ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…
Ahead of schedule on gp-ASIT+
ASIT biotech | 26/02/2019
In a transparent announcement, ASIT Biotech’s board has released the conclusions from its recent meeting. Recruitment for the pivotal Phase III study…
New year, renewed focus
ASIT biotech | 17/01/2019
ASIT has announced renewed focus on its most advanced product, gp-ASIT+ for grass pollen allergies, which coincides with some changes in senior management.…
The 82-centre gp-ASIT+ Phase III study launches
ASIT biotech | 20/11/2018
In a well-received announcement, ASIT has launched the confirmatory Phase III study on gp-ASIT+ for grass pollen allergy with study centres in six European…
Setting the stage for the confirmatory Phase III
ASIT biotech | 27/09/2018
ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for…
All go on Phase III
ASIT biotech | 16/07/2018
On July 11 ASIT biotech raised €12m in commitments in a heavily oversubscribed convertible bond placement. In raising this additional capital, ASIT…